RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
CTI Biopharma Stock

CTI Biopharma Net Income 2025

CTI Biopharma Net Income

76.51 M USD

Ticker

CTIC

ISIN

US12648L6011

WKN

A2DJWX

In 2025, CTI Biopharma's profit amounted to 76.51 M USD, a 64.87% increase from the 46.41 M USD profit recorded in the previous year.

The CTI Biopharma Net Income history

YEARNET INCOME (undefined USD)
2030e-
2029e-
2028e-
2027e183.67
2026e119.04
2025e76.51
2024e46.41
2023e-32.54
2022-92.99
2021-97.91
2020-52.45
2019-40.02
2018-29.4
2017-45.02
2016-52.01
2015-122.62
2014-95.99
2013-49.64
2012-115.28
2011-121.08
2010-147.56
2009-116.76
2008-202.91
2007-148.31
2006-135.82
2005-102.51
2004-252.3
2003-130.03

CTI Biopharma Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into CTI Biopharma, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by CTI Biopharma from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects CTI Biopharma’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of CTI Biopharma. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into CTI Biopharma’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing CTI Biopharma’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on CTI Biopharma’s growth potential.

CTI Biopharma Revenue, EBIT and net profit per share

DateCTI Biopharma RevenueCTI Biopharma EBITCTI Biopharma Net Income
2030e600.47 M undefined0 undefined0 undefined
2029e537.64 M undefined334.66 M undefined0 undefined
2028e469.3 M undefined276.01 M undefined0 undefined
2027e553.52 M undefined315.74 M undefined183.67 M undefined
2026e473.77 M undefined214.31 M undefined119.04 M undefined
2025e345.55 M undefined162.45 M undefined76.51 M undefined
2024e257.94 M undefined87.33 M undefined46.41 M undefined
2023e127.1 M undefined-23.11 M undefined-32.54 M undefined
202253.95 M undefined-79.8 M undefined-92.99 M undefined
20210 undefined-95.33 M undefined-97.91 M undefined
20200 undefined-43.57 M undefined-52.45 M undefined
20193.35 M undefined-39.92 M undefined-40.02 M undefined
201826.29 M undefined-32.24 M undefined-29.4 M undefined
201725.15 M undefined-39.52 M undefined-45.02 M undefined
201657.41 M undefined-49.16 M undefined-52.01 M undefined
201516.12 M undefined-116.67 M undefined-122.62 M undefined
201460.08 M undefined-86.23 M undefined-95.99 M undefined
201334.68 M undefined-41.37 M undefined-49.64 M undefined
20120 undefined-100.56 M undefined-115.28 M undefined
20110 undefined-73.19 M undefined-121.08 M undefined
2010320,000 undefined-78.25 M undefined-147.56 M undefined
200980,000 undefined-87.83 M undefined-116.76 M undefined
200811.43 M undefined-86.73 M undefined-202.91 M undefined
2007130,000 undefined-132.99 M undefined-148.31 M undefined
200680,000 undefined-98.01 M undefined-135.82 M undefined
200516.09 M undefined-116.16 M undefined-102.51 M undefined
200429.59 M undefined-240.83 M undefined-252.3 M undefined
200324.77 M undefined-122.59 M undefined-130.03 M undefined

CTI Biopharma stock margins

The CTI Biopharma margin analysis displays the gross margin, EBIT margin, as well as the profit margin of CTI Biopharma. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for CTI Biopharma.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the CTI Biopharma's sales revenue. A higher gross margin percentage indicates that the CTI Biopharma retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the CTI Biopharma's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the CTI Biopharma's total revenue generated. When comparing the revenue margin year over year, investors can gauge the CTI Biopharma's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the CTI Biopharma. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the CTI Biopharma's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

CTI Biopharma Margin History

CTI Biopharma Gross marginCTI Biopharma Profit marginCTI Biopharma EBIT marginCTI Biopharma Profit margin
2030e93.49 %0 %0 %
2029e93.49 %62.25 %0 %
2028e93.49 %58.81 %0 %
2027e93.49 %57.04 %33.18 %
2026e93.49 %45.24 %25.13 %
2025e93.49 %47.01 %22.14 %
2024e93.49 %33.86 %17.99 %
2023e93.49 %-18.18 %-25.6 %
202293.49 %-147.91 %-172.37 %
202193.49 %0 %0 %
202093.49 %0 %0 %
201993.49 %-1,191.64 %-1,194.63 %
201896.65 %-122.63 %-111.83 %
201798.53 %-157.14 %-179.01 %
201697.6 %-85.63 %-90.59 %
201587.97 %-723.76 %-760.67 %
201498.5 %-143.53 %-159.77 %
201399.6 %-119.29 %-143.14 %
201293.49 %0 %0 %
201193.49 %0 %0 %
201093.49 %-24,453.13 %-46,112.5 %
2009100 %-109,787.5 %-145,950 %
200871.65 %-758.79 %-1,775.24 %
200761.54 %-102,300.01 %-114,084.62 %
2006100 %-122,512.5 %-169,775.01 %
200596.77 %-721.94 %-637.1 %
200496.28 %-813.89 %-852.65 %
200396.61 %-494.91 %-524.95 %

CTI Biopharma Aktienanalyse

What does CTI Biopharma do?

CTI Biopharma Corp is a biopharmaceutical company focused on the development of therapies for the treatment of cancer and other serious diseases. The company was founded in 1991 in Seattle, USA, and has been listed on the NASDAQ stock exchange since 1997. History: The history of CTI Biopharma Corp dates back to 1996 when the company launched its first product, a treatment for chronic myeloid leukemia. Since then, the company has continuously evolved and grown through the acquisition of other companies. In 2014, CTI Biopharma Corp merged with the French companies Cell Therapeutics, and in 2015, it acquired the Italian company Chroma Therapeutics. Business model: CTI Biopharma Corp's business model focuses on the development and commercialization of cancer therapies. The company utilizes its expertise in biology, chemistry, and medicine to develop innovative therapies that target specific molecular targets in tumors. The therapies are developed and produced by CTI Biopharma Corp itself before being distributed by doctors and healthcare facilities. Different divisions: The different divisions of CTI Biopharma Corp focus on various areas of cancer research. The "Hematology" division investigates the treatment of blood diseases such as leukemia and lymphomas. "Oncology," on the other hand, deals with the treatment of solid tumors such as breast cancer and lung cancer. Additionally, CTI Biopharma Corp also works in the field of "Toxicology" by studying the compatibility of medications and their effects on the immune system. Products: CTI Biopharma Corp offers a variety of products, but its flagship product Pixuvri is considered the most outstanding. Pixuvri is a chemotherapy drug used for the treatment of aggressive B-cell non-Hodgkin lymphomas (NHL). The drug is already approved in Europe, where it has been marketed since 2012. Pixuvri is currently under evaluation by the Food and Drug Administration (FDA) for potential introduction into the US market. Another product from CTI Biopharma Corp is Pacritinib, a tablet form used for the treatment of myelofibrosis. Conclusion: CTI Biopharma Corp has specialized in the development of drugs for the treatment of cancer and other diseases over the years. The company has focused on different divisions such as oncology and toxicology and offers a variety of products, including Pixuvri and Pacritinib. The acquisition of Chroma Therapeutics and Cell Therapeutics further highlights CTI Biopharma Corp's expansion strategy. CTI Biopharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Net Income Details

Understanding CTI Biopharma's Profit Margins

The profit margins of CTI Biopharma represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of CTI Biopharma's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating CTI Biopharma's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

CTI Biopharma's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When CTI Biopharma’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about CTI Biopharma stock

How much profit has CTI Biopharma made this year?

CTI Biopharma has made 76.51 M USD this year.

How has the profit developed compared to last year?

The profit has increased by 64.87% compared to last year increased

What impact do the earnings have on the shareholders?

An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.

How does CTI Biopharma publish its earnings?

CTI Biopharma publishes its earnings in the form of quarterly or annual reports.

Which financial indicators are included in the quarterly or annual reports?

The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.

Why is it important for investors to know the earnings of CTI Biopharma?

The profits of CTI Biopharma are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.

How can one learn more about the earnings of CTI Biopharma?

You can learn more about the earnings of CTI Biopharma by reviewing the quarterly or annual reports or following the company presentations.

How much dividend does CTI Biopharma pay?

Over the past 12 months, CTI Biopharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, CTI Biopharma is expected to pay a dividend of 0 USD.

What is the dividend yield of CTI Biopharma?

The current dividend yield of CTI Biopharma is .

When does CTI Biopharma pay dividends?

CTI Biopharma pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of CTI Biopharma?

CTI Biopharma paid dividends every year for the past 0 years.

What is the dividend of CTI Biopharma?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is CTI Biopharma located?

CTI Biopharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von CTI Biopharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of CTI Biopharma from 6/21/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/21/2025.

When did CTI Biopharma pay the last dividend?

The last dividend was paid out on 6/21/2025.

What was the dividend of CTI Biopharma in the year 2024?

In the year 2024, CTI Biopharma distributed 0 USD as dividends.

In which currency does CTI Biopharma pay out the dividend?

The dividends of CTI Biopharma are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von CTI Biopharma

Our stock analysis for CTI Biopharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of CTI Biopharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.